in vitro News and Research

RSS

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.

16 Mar 2010

Nova Century Scientific to market and sell Diamedix’ products in Canada

IVAX Diagnostics, Inc., a fully integrated global invitro diagnostics company, announced that its subsidiary, Diamedix Corporation, has signed a distribution agreement with Nova Century Scientific (“Nova”), a leading Canadian distributor and manufacturer of diagnostic kits and laboratory supplies. Through this agreement, which marks IVAX Diagnostics’ entry into the Canadian market, Nova will market and sell 50 of Diamedix’s products, including analyzer instrumentation, under the Diamedix brand.

16 Mar 2010

Study reveals comparable fertility rates between UFE and surgical myomectomy

Uterine fibroid embolization, a minimally invasive interventional radiology procedure that blocks blood supply to treat painful uterine fibroids, has a comparable fertility rate to myomectomy, the surgical removal of uterine fibroids, for women who want to conceive, according to the first study on the subject released at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

16 Mar 2010

TCAD therapy superior to double combinations and monotherapy against influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses. Results of these studies were presented Sunday evening in an oral session at the XII International Symposium on Respiratory Viral Infections being held in Taipei.

15 Mar 2010

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

Chemotherapy, followed by the surgical removal of the affected tissue is the treatment usually adapted to bone tumors. An implant which can fill the areas of subtraction, while releasing chemotherapeutical agents locally, in a controlled manner, during the treatment period, is the aim of a research led by the Research Centre in Ceramic Material and Composites (CICECO/UA). In these experiences, specialists are using potential "anti-tumor" drugs coated by nanocapsules.

15 Mar 2010

New laboratory technique may help prioritize cancer drugs for clinical trials

Improving on traditional screening tests for potential anti-cancer drugs, scientists at Dana-Farber Cancer Institute have developed a laboratory technique that more closely simulates the real-world conditions in which tumor cells mingle with the body's normal cells.

15 Mar 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010

BeaconEquity.com announces investment report featuring NexMed

BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.

12 Mar 2010

bioMerieux introduces FDA cleared chromID VRE for detecting Enterococcus faecium and Enterococcus faecalis

bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.

12 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

Cytokeratins 8 and 18 can strongly enhance breast cancer drug fulvestrant's anti-estrogenic activity

Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.

11 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

OVA1 blood test aids in pre-surgical evaluation of women for ovarian cancer now available through Quest Diagnostics

OVA1™, the first blood test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the pre-surgical evaluation of a woman's ovarian mass for cancer, is now available nationally through Quest Diagnostics, Inc., the world's leading cancer diagnostics provider.

From Quest Diagnostics 10 Mar 2010

Celltrion develops novel human monoclonal antibodies against influenza virus infection

Celltrion, Inc., a South Korean biopharmaceutical company, has developed novel human monoclonal antibodies against influenza virus infection, which neutralize a broad spectrum of influenza viruses, including pandemic H1N1 and the deadly H5N1 avian influenza virus. Preliminary tests in laboratory animals indicate that the novel human monoclonal antibodies can be used to prevent disease when given either before or after infection.

10 Mar 2010

ZenBio to be commercial source for popular murine 3T3-L1 cell line

ZenBio announce that they will be a commercial source for the popular murine 3T3-L1 cell line, which has been fundamental in metabolic disease research for 30 years.

10 Mar 2010

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.

10 Mar 2010

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.

9 Mar 2010

Usage of gonadotropins in assisted reproductive technologies significantly improves outcomes

The U.S. infertility specialty has empirically incorporated greater amounts of human menopausal gonadotropin (hMG) into stimulation protocols, according to a new review article, "Gonadotropins in the Treatment of Infertility" by George T. Koulianos, MD, published in a recent issue of US Obstetrics & Gynecology, supported by an educational grant from Ferring Pharmaceuticals. The article reviews the wealth of clinical evidence supporting this trend, and demonstrates how the use of gonadotropins in the treatment of infertility, especially in assisted reproductive technologies, has significantly improved outcomes.

9 Mar 2010

Entelos, RegeneMed release iToxFX to screen novel compounds for potential toxicity issues

Entelos, Inc., a simulation and modeling company focused on human health, and RegeneMed, Inc., a tissue-based drug discovery and regenerative medicine company, announced today the release of iToxFX™.

8 Mar 2010

in vitro News and Research

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Nova Century Scientific to market and sell Diamedix’ products in Canada

Study reveals comparable fertility rates between UFE and surgical myomectomy

TCAD therapy superior to double combinations and monotherapy against influenza viruses

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

New laboratory technique may help prioritize cancer drugs for clinical trials

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

BeaconEquity.com announces investment report featuring NexMed

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

bioMerieux introduces FDA cleared chromID VRE for detecting Enterococcus faecium and Enterococcus faecalis

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Cytokeratins 8 and 18 can strongly enhance breast cancer drug fulvestrant's anti-estrogenic activity

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

OVA1 blood test aids in pre-surgical evaluation of women for ovarian cancer now available through Quest Diagnostics

Celltrion develops novel human monoclonal antibodies against influenza virus infection

ZenBio to be commercial source for popular murine 3T3-L1 cell line

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

Usage of gonadotropins in assisted reproductive technologies significantly improves outcomes

Entelos, RegeneMed release iToxFX to screen novel compounds for potential toxicity issues

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News